Shandong Keyuan Pharmaceutical Co Ltd
SZSE:301281
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
25.66
39.7
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Shandong Keyuan Pharmaceutical Co Ltd
Shandong Keyuan Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of chemical raw materials, and chemical preparation. The company is headquartered in Jinan, Shandong. The company went IPO on 2023-04-04. The firm's main products include gliclazide, metformin hydrochloride, ropivacaine hydrochloride and others. The firm's products are used in hypoglycemic, anesthetic, cardiovascular and psychiatric diseases. The firm conducts its operations mainly in the domestic market.
Shandong Keyuan Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of chemical raw materials, and chemical preparation. The company is headquartered in Jinan, Shandong. The company went IPO on 2023-04-04. The firm's main products include gliclazide, metformin hydrochloride, ropivacaine hydrochloride and others. The firm's products are used in hypoglycemic, anesthetic, cardiovascular and psychiatric diseases. The firm conducts its operations mainly in the domestic market.
